Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Inorganic phosphate is essential for ECM mineralization and also as a constituent of important molecules in cellular metabolism. Investigations of several hypophosphatemic diseases indicated that a hormone-like molecule probably regulates serum phosphate concentration. FGF23 has recently been recognized as playing important pathophysiological roles in several hypophosphatemic diseases. We present here the evidence that FGF23 is a physiological regulator of serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D) by generating FGF23-null mice. Disruption of the Fgf23 gene did not result in embryonic lethality, although homozygous mice showed severe growth retardation with abnormal bone phenotype and markedly short life span. The Fgf23(-/-) mice displayed significantly high serum phosphate with increased renal phosphate reabsorption. They also showed an elevation in serum 1,25(OH)2D that was due to the enhanced expression of renal 25-hydroxyvitamin D-1alpha-hydroxylase (1alpha-OHase) from 10 days of age. These phenotypes could not be explained by currently known regulators of mineral homeostasis, indicating that FGF23 is essential for normal phosphate and vitamin D metabolism.

[1]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  K. White,et al.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. , 2003, The Journal of clinical investigation.

[3]  K. White,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[4]  D. Miao,et al.  The Autosomal Dominant Hypophosphatemic Rickets R176Q Mutation in Fibroblast Growth Factor 23 Resists Proteolytic Cleavage and Enhances in Vivo Biological Potency* , 2003, The Journal of Biological Chemistry.

[5]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[6]  T. Yoneya,et al.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. , 2002, Endocrinology.

[7]  T. Strom,et al.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. , 2001, Kidney international.

[8]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Spector,et al.  The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting , 2001 .

[10]  T. Meitinger,et al.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.

[11]  H. DeLuca,et al.  Regulation of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3. , 2000, Archives of biochemistry and biophysics.

[12]  F. Glorieux,et al.  Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. , 2000, Endocrinology.

[13]  M. Traebert,et al.  Regulation of small intestinal Na-Pi type IIb cotransporter by dietary phosphate intake. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[14]  N. Amizuka,et al.  Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Kato,et al.  25-Hydroxyvitamin D3 1α-Hydroxylase and Vitamin D Synthesis , 1997 .

[16]  H. Murer,et al.  A molecular view of proximal tubular inorganic phosphate (Pi) reabsorption and of its regulation , 1997, Pflügers Archiv.

[17]  B. Kaissling,et al.  Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. , 1996, Kidney international.

[18]  A. Vesterby,et al.  Bone histomorphometry in hypoparathyroid patients treated with vitamin D. , 1996, Bone.

[19]  M. Econs,et al.  Tumor-induced osteomalacia--unveiling a new hormone. , 1994, The New England journal of medicine.

[20]  M. Hediger,et al.  Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.

[21]  T. Yagi,et al.  A novel negative selection for homologous recombinants using diphtheria toxin A fragment gene. , 1993, Analytical biochemistry.

[22]  G. Semenza,et al.  A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes. Their use in investigating some properties of D-glucose and choline transport systems. , 1978, Biochimica et biophysica acta.

[23]  K. Isselbacher,et al.  Glucose transport in isolated brush border membrane from rat small intestine. , 1973, The Journal of biological chemistry.

[24]  J. Bilezikian,et al.  Actions of Parathyroid Hormone , 2002 .

[25]  M. Drezner.  PHEX gene and hypophosphatemia. , 2000, Kidney international.